AP200403050A0 - Chemically modified human growth hormone conjugates. - Google Patents

Chemically modified human growth hormone conjugates.

Info

Publication number
AP200403050A0
AP200403050A0 AP200403050A AP200403050A AP200403050A0 AP 200403050 A0 AP200403050 A0 AP 200403050A0 AP 200403050 A AP200403050 A AP 200403050A AP 200403050 A AP200403050 A AP 200403050A AP 200403050 A0 AP200403050 A0 AP 200403050A0
Authority
AP
ARIPO
Prior art keywords
growth hormone
chemically modified
human growth
modified human
hormone conjugates
Prior art date
Application number
AP200403050A
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33190701P priority Critical
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Priority to PCT/US2002/037270 priority patent/WO2003044056A2/en
Publication of AP200403050A0 publication Critical patent/AP200403050A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormones [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
AP200403050A 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates. AP200403050A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33190701P true 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
AP200403050A0 true AP200403050A0 (en) 2004-06-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
AP200403050A AP200403050A0 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates.

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20070072924A (en)
CN (1) CN1608079A (en)
AP (1) AP200403050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA008505B1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HU0500997A2 (en)
IL (1) IL162031D0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and uses thereof
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP1673464A2 (en) * 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
MX2007007590A (en) 2004-12-22 2007-12-10 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides.
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
KR20070100299A (en) * 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 Methods for expression and purification of recombinant human growth hormone
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
KR20080013878A (en) 2005-04-18 2008-02-13 노보 노르디스크 에이/에스 Il-21 variants
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
US20090137736A1 (en) * 2005-11-08 2009-05-28 Ambrx, Inc. Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides
KR101332875B1 (en) 2005-12-14 2013-11-27 암브룩스, 인코포레이티드 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008003750A2 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (en) 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
UA103158C2 (en) 2007-08-16 2013-09-25 Фармаиссеншиа Корп. Protein-polymer conjugate and treating method
PT2272875E (en) 2008-04-03 2014-04-28 Biosteed Gene Expression Tech Co Ltd Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
EA020347B1 (en) * 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Peptide-polymer conjugates
CN102112157B (en) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
JP5766118B2 (en) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション Polymeric alpha - hydroxy aldehydes and ketones reactants and conjugation methods
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
AU2010332958B2 (en) 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
CN103002918B (en) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 In vivo efficacy of prolonged growth hormone
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг The stabilized growth hormone compound
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
CA2978330A1 (en) * 2015-03-11 2016-09-15 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
KR20180052642A (en) * 2015-09-18 2018-05-18 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 Long time action type Adreno Medulin derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (en) * 1990-05-04 1998-05-01 American Cyanamid Co Stabilization somatotropins and other proteins by modification of cysteine ​​residues.
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69635026T2 (en) * 1995-09-21 2006-05-24 Genentech Inc., San Francisco Variants of the human growth hormone
JP2001510033A (en) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー, インコーポレイテッド Derivatives of growth hormone and related proteins
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2204509T3 (en) * 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag GCSF conjugates.
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Kim Vilbour Andersen Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
HRP20040448A2 (en) 2006-02-28
EA200400565A1 (en) 2005-06-30
ECSP045114A (en) 2004-07-23
MA27544A1 (en) 2005-10-03
MXPA04004809A (en) 2004-08-11
EA200700431A1 (en) 2008-02-28
JP2006321808A (en) 2006-11-30
CO5580794A2 (en) 2005-11-30
AU2002356990A1 (en) 2003-06-10
HU0500997A2 (en) 2007-11-28
JP2005525302A (en) 2005-08-25
EA008505B1 (en) 2007-06-29
WO2003044056A2 (en) 2003-05-30
OA13063A (en) 2006-11-10
IS7268A (en) 2004-05-17
GEP20063860B (en) 2006-06-26
ZA200403907B (en) 2007-12-27
CN1608079A (en) 2005-04-20
NO20042182L (en) 2004-08-11
EP1453859A2 (en) 2004-09-08
KR20070072924A (en) 2007-07-06
WO2003044056A3 (en) 2003-08-21
CA2467731A1 (en) 2003-05-30
RS53104A (en) 2006-10-27
TNSN04090A1 (en) 2006-06-01
BR0214451A (en) 2006-05-30
IL162031D0 (en) 2005-11-20
PL374354A1 (en) 2005-10-17
KR20050044858A (en) 2005-05-13

Similar Documents

Publication Publication Date Title
GB2346165B (en) Flexible swage
TWI304407B (en) Superabsorbents, preparation thereof and use thereof
GB2365898B (en) Self-lubricating swage
GB0001704D0 (en) Protein
AU2002321888A1 (en) Medical needle
ZA200301524B (en) Vaccine.
AU7814201A (en) Common application metamodel including c/c++ metamodel
PL212614B1 (en) Furrow opener
HK1036926A1 (en) Longitudinally flexible stent.
AU2002333733A1 (en) Implant
AU4196301A (en) Improved medical procedure
AU2002249391A1 (en) Implant
ZA200202161B (en) Chair.
AU1797902A (en) Medicine feeder
ZA200203764B (en) Inhaler.
MXPA03008961A (en) Vaccine composition.
MXPA03009149A (en) Money-transfer techniques.
ZA200303062B (en) 4-amino-quinazolines.
AU8175801A (en) Biocompatible materials
ZA200204165B (en) Fulvestrant formulation.
ZA200301436B (en) Cripto tumour polypeptide.
AU2001262829A1 (en) Medical arrangement
PL362413A1 (en) Modified anti-egfr antibodies with reduced immunogenicity
AU1136602A (en) Human anti-cd40 antibodies
ZA200206544B (en) Foam-on-film medical articles.